Armen Yuri Gasparyan

Armen Yuri Gasparyan

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Armen Yuri Gasparyan

Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
AGArmen Yuri Gasparyan
Armen Yuri Gasparyan
LALilit Ayvazyan
Lilit Ayvazyan
DMDimitri P. Mikhailidis
Dimitri P. Mikhailidis
GKGeorge D. Kitas
George D. Kitas
Platelet activation is a link in the pathophysiology of diseases prone to thrombosis and inflammation. Numerous platelet markers, including mean platelet volume (MPV), have been investigated in connection with both thrombosis and inflammation. This review considers MPV as a prognostic and therapeutic marker as well as the factors influencing its measurement. Established cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, and diabetes, can influence MPV, depending on confounding factors. Low-grade inflammation is one such factor. Evidence, particularly derived from prospective studies and a meta-analysis, suggest a correlation between an increase in MPV and the risk of thrombosis. High MPV associates with a variety of established risk factors, cardio- and cerebrovascular disorders, and low-grade inflammatory conditions prone to arterial and venous thromboses. High-grade inflammatory diseases, such as active rheumatoid arthritis or attacks of familial Mediterranean fever, present with low levels of MPV, which reverse in the course of antiinflammatory therapy. Lifestyle modification, antihypertensive, lipid-lowering and diet therapies can also affect MPV values, but these effects need to be investigated in large prospective studies with thrombotic endpoints.

29 July 2011 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AGArmen Yuri Gasparyan
Armen Yuri Gasparyan
LALilit Ayvazyan
Lilit Ayvazyan
HBHeather Blackmore
Heather Blackmore
GKGeorge D. Kitas
George D. Kitas

1 July 2019 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
AGArmen Yuri Gasparyan
Armen Yuri Gasparyan
LALilit Ayvazyan
Lilit Ayvazyan
UMUlzhan Mukanova
Ulzhan Mukanova
MYMarlen Yessirkepov
Marlen Yessirkepov
GKGeorge D. Kitas
George D. Kitas
Gasparyan AY, et al. Ann Lab Med. 2019 Jul;39(4):345-357. https://doi.org/10.3343/alm.2019.39.4.345

1 May 2008 in JACC
Verified
Journal Article
Closed access
AGArmen Yuri Gasparyan
Armen Yuri Gasparyan
TWTimothy Watson
Timothy Watson
GLGregory Y.H. Lip
Gregory Y.H. Lip

11 July 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
SASakir Ahmed
Sakir Ahmed
OZOlena Zimba
Olena Zimba
AGArmen Yuri Gasparyan
Armen Yuri Gasparyan

10 April 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
VAVikas Agarwal
Vikas Agarwal
AGArmen Yuri Gasparyan
Armen Yuri Gasparyan
OZOlena Zimba
Olena Zimba